Nilsson C - Search Results

1

Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals.

Lizeng Q, Nilsson C, Sourial S, Andersson S, Larsen O, Aaby P, Ehnlund M, Björling E. Lizeng Q, et al. Among authors: nilsson c. J Virol. 2004 Jul;78(13):7016-22. doi: 10.1128/JVI.78.13.7016-7022.2004. J Virol. 2004. PMID: 15194778 Free PMC article.

2

Broadly reactive HIV-2 and SIVmac specific antibody-dependent cellular cytotoxicity in immunized and infected cynomolgus monkeys.

von Gegerfelt A, Nilsson C, Putkonen P, Broliden K. von Gegerfelt A, et al. Among authors: nilsson c. Vaccine. 1994 Oct;12(13):1203-8. doi: 10.1016/0264-410x(94)90244-5. Vaccine. 1994. PMID: 7839725

3

Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge.

Zuber B, Hinkula J, Vödrös D, Lundholm P, Nilsson C, Mörner A, Levi M, Benthin R, Wahren B. Zuber B, et al. Among authors: nilsson c. Virology. 2000 Dec 20;278(2):400-11. doi: 10.1006/viro.2000.0633. Virology. 2000. PMID: 11118363 Free article.

4

Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys.

Walther-Jallow L, Nilsson C, Söderlund J, Ten Haaft P, Mäkitalo B, Biberfeld P, Böttiger P, Heeney J, Biberfeld G, Thorstensson R. Walther-Jallow L, et al. Among authors: nilsson c. J Gen Virol. 2001 Jul;82(Pt 7):1601-1612. doi: 10.1099/0022-1317-82-7-1601. J Gen Virol. 2001. PMID: 11413371

5

Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection.

Lizeng Q, Skott P, Sourial S, Nilsson C, Andersson S S, Ehnlund M, Taveira N, Björling E. Lizeng Q, et al. Among authors: nilsson c. Virology. 2003 Apr 10;308(2):225-32. doi: 10.1016/s0042-6822(02)00088-0. Virology. 2003. PMID: 12706073 Free article.

6

Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen.

Mäkitalo B, Lundholm P, Hinkula J, Nilsson C, Karlén K, Mörner A, Sutter G, Erfle V, Heeney JL, Wahren B, Biberfeld G, Thorstensson R. Mäkitalo B, et al. Among authors: nilsson c. J Gen Virol. 2004 Aug;85(Pt 8):2407-2419. doi: 10.1099/vir.0.79869-0. J Gen Virol. 2004. PMID: 15269383

7

Cloning, expression, and purification of HIV-2 gp125: A target for HIV vaccination.

Sourial S, Wärnmark A, Nilsson C, Björling E, Achour A, Harris RA. Sourial S, et al. Among authors: nilsson c. Mol Biotechnol. 2005 Jun;30(2):155-62. doi: 10.1385/MB:30:2:155. Mol Biotechnol. 2005. PMID: 15920286

8

Deletion of the V1/V2 region does not increase the accessibility of the V3 region of recombinant gp125.

Sourial S, Nilsson C, Wärnmark A, Achour A, Harris RA. Sourial S, et al. Among authors: nilsson c. Curr HIV Res. 2006 Apr;4(2):229-37. doi: 10.2174/157016206776055066. Curr HIV Res. 2006. PMID: 16611061

9

HIV-2 neutralization by intact V3-specific Fab fragments.

Sourial S, Nilsson C. Sourial S, et al. Among authors: nilsson c. Virol J. 2008 Aug 18;5:96. doi: 10.1186/1743-422X-5-96. Virol J. 2008. PMID: 18706111 Free PMC article.

10

Comparison of the performance of rapid HIV tests using samples collected for surveillance in Mozambique.

Melo J, Nilsson C, Mondlane J, Osman N, Biberfeld G, Folgosa E, Andersson S. Melo J, et al. Among authors: nilsson c. J Med Virol. 2009 Dec;81(12):1991-8. doi: 10.1002/jmv.21633. J Med Virol. 2009. PMID: 19856475

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,092 results

Search Page

Filters